Form 4: Acadia Pharmaceuticals CFO Sells Shares to Cover Taxes After Stock Unit Vesting

Acadia Pharmaceuticals' CFO, Mark C. Schneyer, sold 10,259 shares of common stock at an average price of $16.81 to cover tax obligations related to the vesting of restricted stock units.

Summary

• Mark C. Schneyer, the Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals, engaged in transactions involving the company's stock.
• On November 17, 2024, Schneyer acquired 9,913 shares through the vesting of restricted stock units.
• On the same day, he acquired another 9,913 shares through the vesting of additional restricted stock units.
• Subsequently, on November 19, 2024, Schneyer sold 10,259 shares at a weighted average price of $16.81 per share.
• The sale was made to cover withholding taxes and tax-related items associated with the vesting of the restricted stock units.
• Following these transactions, Schneyer directly owns 53,302 shares of Acadia Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment. It is a standard practice for executives to sell shares to cover taxes.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units, with 37.5% vesting after 18 months and the remainder vesting over the following years, is a fairly standard practice in the pharmaceutical industry for executive compensation.
• The sale of shares to cover tax obligations is also a common practice among executives in publicly traded companies, including those in the pharmaceutical sector.
• Companies like Biogen, Amgen, and Gilead Sciences also use restricted stock units as part of their executive compensation packages, and their executives often engage in similar transactions.

Stakeholder Impact

• The sale of shares by the CFO is unlikely to have a significant impact on shareholders, as it is a routine transaction related to executive compensation.
• The sale was made to cover tax obligations, which is a standard practice and does not indicate any change in the company's fundamentals.

Key Dates

Keywords

Acadia Pharmaceuticals, stock sale, restricted stock units, insider trading, Form 4, executive compensation, tax obligations, share vesting